ADCT (ADC Therapeutics) Total Liabilities : $524.62 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Total Liabilities?

ADC Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was $524.62 Mil.

ADC Therapeutics's quarterly Total Liabilities increased from Jun. 2024 ($503.45 Mil) to Sep. 2024 ($521.03 Mil) and increased from Sep. 2024 ($521.03 Mil) to Dec. 2024 ($524.62 Mil).

ADC Therapeutics's annual Total Liabilities increased from Dec. 2022 ($411.41 Mil) to Dec. 2023 ($503.03 Mil) and increased from Dec. 2023 ($503.03 Mil) to Dec. 2024 ($524.62 Mil).

ADC Therapeutics Total Liabilities Historical Data

The historical data trend for ADC Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Total Liabilities Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

178.19

451.88

411.41

503.03

524.62

ADC Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															503.03	502.42	503.45	521.03	524.62

ADC Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ADC Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	80.469	+	(121.627	+	2.4329999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	320.093	+	0	+	0)
	=	524.62

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	321.98	-	-202.642
	=	524.62

ADC Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	80.469	+	(121.627	+	2.4329999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	320.093	+	0	+	0)
	=	524.62

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	321.98	-	-202.642
	=	524.62

ADC Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).